Sign in

    Mick (on behalf of Roanna Ruiz)

    Senior Managing Director and Senior Biotechnology Analyst at Leerink Partners

    Mick (on behalf of Roanna Ruiz) is a Senior Managing Director and Senior Biotechnology Analyst at Leerink Partners, specializing in biopharma with a focus on cardiovascular, endocrine disorders, and infectious disease companies. She has covered a range of biopharmaceutical firms, delivering deep-dive, science-driven investment research and is recognized for the quality and insightfulness of her analysis; her recommendations have consistently outperformed the sector average and have earned positive recognition internally and externally. Starting her career in equity research at UBS and H.C. Wainwright before joining Leerink Partners in 2018, she was promoted rapidly to senior leadership and previously contributed to M&A and strategy projects as a consultant at IQVIA. Ruiz holds a Ph.D. in Biomedical Engineering from Cornell University, a B.S. from Harvard, and maintains active industry registrations and securities licenses relevant for senior equity research analysts.

    Mick (on behalf of Roanna Ruiz)'s questions to ENANTA PHARMACEUTICALS (ENTA) leadership

    Mick (on behalf of Roanna Ruiz)'s questions to ENANTA PHARMACEUTICALS (ENTA) leadership • Q2 2024

    Question

    The analyst asked about the enrollment status of the final cohort in the RSVPEDs study and the subsequent data timeline. They also inquired about the desired safety profile and dosing frequency for the future oral KIT inhibitor for CSU.

    Answer

    The company is in the "home stretch" of enrolling the final cohort (20 patients, aged 28 days to 6 months) for the RSVPEDs study. For the CSU program, they are targeting a once-daily (QD) candidate with a best-in-class safety profile, good potency, and high selectivity, with plans to select the final candidate in Q4.

    Ask Fintool Equity Research AI